Silicosis Model

Model Introduction

The Silicosis animal model involves introducing silica (SiO2) dust into the lungs of experimental animals to simulate the process of diffuse pulmonary fibrosis caused by the inhalation of industrial dust in occupational exposure environments. This model aims to overcome the limitations of human studies (such as epidemiological investigations and lung biopsies) that make it difficult to observe the entire disease process dynamically and systematically, providing an experimental basis for exploring the pathogenesis, pathological evolution, and clinical treatment plans of silicosis.

Research Applications

This model is mainly used in the following research fields:

1. Pathogenesis Research: Dynamic observation of the entire process from early inflammatory response and inflammatory cell infiltration to late-stage lung tissue fibrosis, and exploring the relationship between inflammatory factor release and the degree of fibrosis.
2. Clinical Treatment and Drug Screening: Providing an experimental carrier for the efficacy evaluation and toxicological research of silicosis treatment drugs.
3. Early Screening Research: Facilitating research on early screening indicators for occupational dust-exposed populations.
4. Pathology and Imaging Comparison: Utilizing large animal models (e.g., rabbits) for high-resolution CT scanning to study the laws of lesion evolution.

Experimental Design Key Points

1. Experimental Animal Selection:
   • Rodents: Rats (Wistar and SD strains are common and technically mature); Mice (ICR, Kunming, C57BL/6, Balb/c, convenient for large-scale experiments).
   • Non-rodents: Rabbits (thin pleura, long lifespan, conducive to long-term observation and lung lavage); Dogs (large body size, more conducive to clinical experimental research).
2. Modeling Methods and Parameters:
   • Single Tracheal Instillation:
     • Exposure Method: Injecting SiO2 suspension through a neck tracheal incision. The common dose for rats is 1 ml (50 mg/ml), and for mice, the dose range varies from 0.05 ml to 0.1 ml.
     • Non-exposure Method: Injection via oral intubation or endoscopic guidance.
   • Inhalation Dusting (Dynamic/Dusting Cabinet): Simulating natural breathing states. For example, mice are continuously dusted at a concentration of 125 mg/m³ for 3 weeks (2-8h daily).
   • Dust Treatment: SiO2 standards must be ground in an agate mortar for more than 2 hours to ensure that more than 90% of the dust particles have a diameter < 5 μm.
3. Surgical Operation: The animal must be rotated immediately after instillation to ensure even distribution of the suspension in both lungs; the surgical process must be completed under sterile conditions to reduce interference.

Key Monitoring Indicators

1. Clinical Signs: Observation of animal appetite, activity level, mental state, and body weight changes.
2. Gross Pathological Observation:
   • Lung Morphology: Checking lung surface color (whether grayish-white), texture (whether hardened), and elasticity (whether decreased).
   • Lesion Characteristics: Observing the presence of nodular shadows, punctate hemorrhage, congestion, and edema.
3. Histopathological Evaluation:
   • Pulmonary dust macule count and fibrosis degree grading.
   • Inflammatory response and inflammatory cell infiltration.
4. Biochemical and Molecular Indicators:
   • Cytokine expression levels.
   • Monitoring of protein oxidation status.
   • Component testing of Bronchoalveolar Lavage Fluid (BALF).
5. Imaging Examination: High-resolution CT scans can be used for large animals such as rabbits to observe lung lesions.